The latest industry analysis on Glioblastoma Multiforme Treatment provides sales outlook in 20+ countries, across key categories Product, Application, Sales Channel. Insights on Glioblastoma Multiforme Treatment market drivers, trends, and influencing factors are included in the study.

The detailed research report on the global Glioblastoma Multiforme Treatment market focuses on the macro as well as microeconomic factors that are helping its development. The report also concentrates on the regulatory framework that is shaping the future of the global market. Furthermore, the research report also makes not of the existing as well as prevailing pricing structure, emerging areas of applications, and imminent investment opportunities in the global market.

Get a Free Sample Copy with Impact Analysis of COVID-19 Of Market Report – https://www.factmr.com/connectus/sample?flag=S&rep_id=7187

The Glioblastoma Multiforme Treatment study outlines the North America, South America, Asia and Europe along with the countries contributing the most in the respective regions. The report presents detailed insights about each market player, including SWOT analysis, main market information, market share, revenue, pricing and gross margin.

Key Takeaways from the Market Study

  • Global Glioblastoma Multiforme Treatment Market is estimated to reach a market size of US$ 2.9 Bn by 2022.
  • The Surgery segment is expected to grow at the highest CAGR rate of over 12% during the forecast period.
  • United states is projected to remain the dominant country with absolute dollar opportunity of US$ 1.8 Bn.
  • The market in Japan is set to experience the highest CAGR of 12.8% during the 2022-2032 forecast period.

Competitive Landscape

The market is fiercely competitive, Key players are increasingly focused to obtain a competitive advantage, key companies in the glioblastoma multiforme treatment market are focused on R&D to produce innovative technological products.

  • In April 2021, Lineage Cell Therapeutics signed an agreement with Immunomic Therapeutics to treat glioblastoma multiforme. Under the agreement terms, Lineage will receive a $2 million upfront payment, followed by $67 million in future commercial milestones.
  • In July 2020, Denovo Biopharma, a California-based biotech company, received the FDA’s approval for its phase 2b clinical trial for an analytical combination therapy against glioblastoma tumor tissue.
  • In May 2019, Merck announced its payment of over US$ 1 Bn to complete the acquisition of Peloton Therapeutics, which aims to prevent stroke in patients with glioblastoma using this drug. This M&A holds significant potential to increase Merck’s pipeline and improve their financial ability.

Market Segments Covered in Glioblastoma Multiforme Treatment Market Analysis

By Treatment:

  • Surgery
  • Radiation Therapy
  • Chemotherapy
  • Targeted Therapy
  • Tumor Treating Field (TTF) Therapy
  • Immunotherapy

By Drug Class:

  • Temozolomide
  • Bevacizumab
  • Carmustine Wafers
  • Other Drug Classes
  • Lomustine

By Application:

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers

By Region:

  • North America
  • Latin America
  • Europe
  • APAC
  • MEA

More Insights Available

Fact.MR, in its new offering, presents an unbiased analysis of the Glioblastoma Multiforme Treatment Market, presenting historical market data (2017-2021) and forecast statistics for the period of 2022-2032.